- Tirzepatide achieves 22.5% average weight loss at 3 years, compared to 15% for semaglutide, per 2025 SURMOUNT extension data
- Muscle mass loss averages 8% alongside fat loss — without resistance training, users lose meaningful lean tissue
- HbA1c reductions of 1.5–2.1% persist at 3 years, reducing cardiovascular event risk by an estimated 14%
- Start resistance training and hit 1.6g/kg/day protein before or alongside GLP-1 therapy to protect muscle
Section 1 — Where We Are Three Years In
When semaglutide (Ozempic/Wegovy) launched as a weight loss drug in 2021, it was called revolutionary. The claims were not wrong — but they were incomplete. Now, in early 2026, we have three-year follow-up data from multiple large trials, and the picture is considerably more nuanced than early headlines suggested.
The core story: GLP-1 receptor agonists work. They produce significant, sustained weight loss that no other pharmacological class has matched outside of bariatric surgery. But the emerging concern — one that the biohacking and longevity communities are rightly fixated on — is body composition. Weight loss is not inherently good. Fat loss is good. Losing a meaningful fraction of muscle mass while chasing a lower number on the scale is a trade-off that deserves serious scrutiny.
For tech workers and biohackers who track body composition metrics, this distinction is not academic. Muscle mass is increasingly understood as a primary longevity biomarker. The goal of GLP-1 therapy, properly executed, should be fat loss with muscle preservation — and the 3-year data tells us that achieving this requires active intervention beyond simply taking the drug.
Section 2 — The Evidence
The SURMOUNT-1 extension trial, published in late 2025, followed 938 participants on tirzepatide for 36 months. Average body weight reduction was 22.5% from baseline, with 45% of participants maintaining greater than 20% weight loss. This is the kind of durability that previously only bariatric surgery achieved.
Semaglutide's STEP-5 extension data is slightly less impressive but still clinically meaningful: 15–17% weight loss sustained at 3 years in non-diabetic adults with obesity. The SELECT cardiovascular outcomes trial, now with extended follow-up, showed a 20% reduction in major adverse cardiovascular events (MACE) in people with established cardiovascular disease — making this the most compelling outcome data for the drug class.
The muscle story is where the community discourse is ahead of mainstream medicine. A 2025 analysis published in Obesity Reviews pooled data from 14 GLP-1 trials and found that lean mass loss represented approximately 25–39% of total weight lost. For a person losing 25 kilograms, that's potentially 6–10 kilograms of muscle, which translates directly to reduced strength, lower resting metabolic rate, and worse long-term metabolic outcomes.
Critically, two RCTs published in 2025 found that concurrent resistance training significantly attenuated this muscle loss — participants who performed structured strength training twice weekly lost roughly 60% less lean mass while achieving equivalent fat loss. This is now considered standard-of-care guidance by most obesity medicine specialists, though it is still inadequately communicated to patients.
On the metabolic health front, the HbA1c data is compelling for both diabetic and pre-diabetic individuals. Tirzepatide's dual GIP/GLP-1 mechanism produces HbA1c reductions of 1.5–2.1% at 3 years — exceeding any single oral antidiabetic agent and rivaling insulin in efficacy. For the estimated 96 million American pre-diabetics, this raises serious questions about earlier pharmaceutical intervention.
Section 3 — Practical Protocol
| Drug | Avg Weight Loss (3yr) | Muscle Risk | Monthly Cost (US) | Cardiovascular Benefit |
|---|---|---|---|---|
| Tirzepatide (Zepbound) | 22.5% | High without exercise | $1,060/mo | Emerging data, promising |
| Semaglutide (Wegovy) | 15–17% | High without exercise | $1,300/mo | Strong (SELECT trial) |
| Semaglutide (compounded) | 15% | High without exercise | $200–400/mo | Assumed equivalent |
| Liraglutide (Saxenda) | 8–10% | Moderate | $650/mo | Modest |
| Lifestyle only | 5–8% | Low with training | $0–50/mo | Strong (long-term) |
For biohackers considering GLP-1 therapy, the practical protocol should include: establishing a resistance training baseline of at least two sessions per week before starting the drug; targeting 1.6–2.2g of protein per kilogram of body weight daily (this is non-negotiable on a drug that dramatically suppresses appetite); and tracking DEXA scans or body composition via validated bioimpedance at baseline and every 3 months.
Compounded semaglutide deserves a note. The FDA ban on compounded versions was reversed in mid-2025 following supply normalization and subsequent advocacy. Compounded versions remain legal in many states with prescriptions, but quality control varies enormously. If using a compounding pharmacy, verify USP 797 and 503A compliance.
Section 4 — What to Watch Out For
The average GLP-1 user loses 25–39% of their total weight as lean mass. Without concurrent resistance training, this means meaningful loss of the longevity biomarker that matters most. Do not assume the drug "takes care of everything."
The rebound data is sobering and underreported. The STEP-4 trial showed that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. This has two implications: first, GLP-1 therapy may be a long-term or permanent commitment for many users; second, the underlying metabolic and behavioral drivers of weight gain must be addressed in parallel.
Gastrointestinal side effects — nausea, vomiting, gastroparesis — affect up to 44% of users in the first 12 weeks. The titration schedule matters enormously. Rushing to therapeutic dose is the primary driver of discontinuation. The community-discovered strategy of very slow titration (half the standard dose increase schedule) significantly reduces adverse effects and is now supported by some prescribers.
Thyroid concerns: GLP-1 drugs carry a black-box warning for medullary thyroid carcinoma in rodent models. Human epidemiological data has not confirmed this signal after five-plus years of widespread use, but individuals with a personal or family history of MEN2 or medullary thyroid cancer should avoid the drug class entirely.
Verdict
GLP-1 drugs are the most effective pharmacological weight loss intervention ever approved, with compelling cardiovascular outcome data at 3 years. The primary risk — muscle loss — is preventable with resistance training and adequate protein. The primary limitation — cost — remains a major access barrier at $1,000+/month without insurance coverage. For biohackers who can access the drugs and commit to a structured exercise protocol, the benefit-to-risk ratio is among the best in evidence-based medicine.
Not medical advice. Consult a physician before making changes.
— iBuidl Research Team